481659-93-2Relevant academic research and scientific papers
In vitro and in vivo profile of 5-[(4′-trifluoromethyl-biphenyl-2-carbonyl)-amino]-1H-indole-2-carboxylic acid benzylmethyl carbamoylamide (dirlotapide), a novel potent MTP inhibitor for obesity
Li, Jin,Bronk, Brian S.,Dirlam, John P.,Blize, Alan E.,Bertinato, Peter,Jaynes, Burton H.,Hickman, Anne,Miskell, Christine,Pillai, Usha A.,Tibbitts, Jay S.,Haven, Michelle L.,Kolosko, Nicole L.,Barry, Chris J.,Manion, Tara B.
, p. 1996 - 1999 (2008/02/08)
The synthesis of a novel gut selective MTP inhibitor, 5-[(4′-trifluoromethyl-biphenyl-2-carbonyl)-amino]-1H-indole-2-carboxylic acid benzylmethyl carbamoylamide (dirlotapide), and its in vitro and in vivo profile are described. Dirlotapide (3) demonstrate
Triamide-substituted heterobicyclic compounds
-
, (2008/06/13)
The invention relates to triamide MTP/ApoB inhibitors of the formula 1 wherein R1-R8 are as defined in the specification, as well as pharmaceutical compositions and uses thereof, and processes for preparing the compounds. The compounds of the invention are useful for the treatment of obesity and lipid disorders.
